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Abstract 
Background: The prevention of cardiovascular disease, including diastolic cardiac dysfunction with its high preva‑
lence and ominous prognosis, is a therapeutic challenge for patients with type 2 diabetes. Both short and long‑acting 
insulin analogues (AI) have been shown to reduce glucose variability and provide potential benefit for cardiovascular 
disease although the effects on cardiac function have not yet been evaluated. This long‑term, prospective, rand‑
omized controlled trial in patients with type 2 diabetes (T2D) tested the hypothesis that a multiple daily injection 
regimen (MDI) with AI improves postmeal glucose excursions in comparison to human insulin (HI) and that the effects 
of AI improve diastolic cardiac function.
Methods: For 36 months, MDI treatment in 109 T2D patients was adapted every 3 months (targets: fasting glu‑
cose ≤ 110 mg/dl, postmeal glucose ≤ 150 mg/dl) in both groups: AI (insulin detemir and insulin aspart, n = 61) and 
HI (NPH‑insulin and regular HI, n = 48). Diastolic cardiac function (myocardial velocity E’ using tissue Doppler imag‑
ing and the mitral inflow ratio E/A) and vascular function were assessed before and 2 h after a standardized breakfast 
(48 g carbohydrates). At baseline, both groups were comparable with regards to demographic, cardiac and metabolic 
data. Analysis of data included traditional statistics as well as the use of a multiple imputation technique shown in 
brackets [ ].
Results: At 36 months, the primary endpoint, postmeal glucose, decreased by 20 ± 62 mg/dl, p = 0.038 [p = 0.021] 
with AI and increased insignificantly with HI (inter‑group p = 0.032 [p = 0.047]) to postmeal glucose levels of 
161 ± 39 with AI vs. 195 ± 54 mg/dl with HI (inter‑group p = 0.002 [p = 0.010]) whereas the levels of fasting glucose 
and HbA1c were comparable. With AI, postmeal E’ improved by 0.6 ± 1.4 cm/s, p = 0.009 [p = 0.002] and fasting E’ by 
0.4 ± 1.4 cm/s, p = 0.069 [p = 0.013], however, E’ remained unchanged with HI. These changes were consistent with 
those of the traditional parameter E/A.
Conclusions: MDI with AI results in better postmeal glucose control compared to HI. The treatment with AI is associ‑
ated with improved diastolic cardiac function.
ClinicalTrials.gov (NTC00747409)
© 2016 von Bibra et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Cardiovascular Diabetology
*Correspondence:  vonbibra@gmx.de 
†Joint first authorship between Helene von Bibra and Thorsten Siegmund
1 Clinic for Endocrinology, Diabetes and Vascular Medicine, Klinikum 
Bogenhausen, Städt. Klinikum München GmbH, Munich, Germany
Full list of author information is available at the end of the article
Page 2 of 11von Bibra et al. Cardiovasc Diabetol  (2016) 15:7 
Background
Cardiovascular disease including heart failure is the 
leading cause for morbidity and mortality in people 
with diabetes mellitus making adequate therapy manda-
tory [1]. Diastolic cardiac function is already impaired 
in the pre-diabetic phase (impaired glucose tolerance) 
and brings with it an increased risk of heart failure [2, 
3]. Based on the association of cardiac dysfunction with 
fasting and postmeal metabolic control [4, 5], diagnosis 
and monitoring of sub-clinically impaired cardiac func-
tion may be valuable for monitoring therapeutic efficacy 
[6]. As well in the pre-diabetic phase, the prevalence of 
myocardial infarction is alarming [7]. As consequently 
suggested, the improvement of postprandial metabolism, 
that is a reduction of glucose excursions, should be made 
a cornerstone in metabolic control for the prevention of 
cardiovascular disease [8–10], thereby shifting the focus 
from previous landmark studies related to the HbA1c, an 
overall mean glucose value, to cardiovascular risk. Taking 
this risk and that of heart failure in diabetes mellitus into 
account, the best risk–benefit ratio exists for metformin 
and insulin [11]. In particular, the more recently-devel-
oped short-acting insulin analogues have shown superior 
control of postprandial glucose levels [12] and a reduc-
tion in cardiovascular events [13]. Likewise long-acting 
analogue insulin preparations with their flatter profile 
have shown advantages in day-to-day glucose variabil-
ity compared to human insulin [14]. Consequently, the 
combination of short and long-acting insulin analogues 
(AI) in a multiple daily injection regimen (MDI) theoreti-
cally offers cumulative effects for the reduction of glucose 
excursions/variability.
Whether MDI with AI can improve myocardial dys-
function in patients with type 2 diabetes has not yet been 
assessed. As a proof of concept, this prospective, rand-
omized, open, long-term study tested the hypothesis that 
MDI with AI improves postprandial glucose better than 
human insulin (HI). Furthermore, a beneficial effect of AI 
on diastolic cardiac function was to be evaluated.
Methods
Patients
This prospective long-term (36  months) study on the 
comparison of AI versus HI for MDI regimens randomly 
assigned 124 Caucasian subjects with insulin-treated 
type 2 diabetes either to treatment with analogue insulin 
or human insulin (Fig. 1). All patients attended the Clinic 
of Endocrinology, Diabetes and Vascular Medicine of the 
Academic Teaching Hospital Bogenhausen in Munich 
between 2004 and 2009. Included were patients with 
insulin-treated type 2 diabetes of both sexes between 
35 and 85  years after having submitted their written, 
informed consent. Exclusion criteria were increased left 
ventricular diameter (>55  mm), any signs or history of 
heart failure, >mild grade valvular heart disease, pericar-
dial disease, atrial fibrillation, severe diabetic neuropathy 
or retinopathy, creatinine >2 mg/dl and untreated thyroid 
dysfunction.
The study was conducted in accordance with the Decla-
ration of Helsinki and Good Clinical Practice Guidelines. 
The protocol and the consent form were reviewed by the 
local independent ethics committee before the start of 
the trial.
Randomization and masking
Using an independently-generated randomization list, 
patients were consecutively assigned to one of two insulin 
regimens after enrollment: AI (insulin aspart and insulin 
detemir; insulin by Novo Nordisk, Bagsvaerd, Denmark) 
or HI (regular insulin and NPH; insulin by Novo Nordisk, 
Bagsvaerd, Denmark). An open label design was used as 
the administration time of the meal-related insulin dif-
fered between the two insulin regimens. However, any 
staff involved in ultrasound investigations, blood tests or 
the definition of data sets for statistical analysis remained 
blinded until the database was locked.
Procedures
At the initial visit, all participants were instructed on 
how to measure plasma glucose and how to adjust the 
doses of fast-acting and long-acting insulin and each 
received an electronic device for plasma glucose deter-
minations (ACCU-CHEK® SENSOR, Roche, Grenzach, 
Germany). Treatment targets were defined as ≤110 mg/
dl for fasting plasma glucose and ≤150  mg/dl for post-
prandial plasma glucose. At clinic visits every 3 months, 
participants received individual recommendations by a 
diabetologist for adjusting insulin doses based on their 
self-measured plasma glucose levels in order to achieve 
the specified glucose targets. All patients received indi-
vidualized advice concerning diet, exercise and lifestyle 
in accordance with the guidelines [15].
At baseline and during clinic visits at 12, 24, and 
36  months, the following measurements were taken: 
weight, blood tests and ultrasound examinations in the 
fasting state prior to the morning dose of fast-acting 
Keywords: Analogue insulins, Human insulin, Postprandial glucose, Metabolic control, Diastolic cardiac function, 
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insulin. Blood and ultrasound examinations were 
repeated 2 h after a standardized meal that consisted of 
carbohydrates of mixed glycemic index (48  g) without 
butter and protein [5] and administration of the morn-
ing dose of meal-related insulin (usual type and dose of 
insulin for this meal). Daily insulin doses, state of diabetic 
complications, concomitant medication and its changes 
were documented, as well as cardiovascular adverse 
events as defined by hard endpoints (myocardial infarc-
tion, stroke and cardiovascular death) and soft endpoints 
such as heart failure, coronary angiography, percutane-
ous transluminal coronary angioplasty, new/worsening 
angina pectoris, claudication and amputation.
The primary study endpoint was the change of post-
prandial plasma glucose from baseline to the end of study 
at 36 months.
Secondary endpoints were changes in cardiac diastolic 
function as well as changes in cardiovascular function 
and metabolic variables such as.
  • diastolic myocardial function measured as myocar-
dial velocity E’ (cm/s), transmitral inflow ratio E/A, 
E/E’,
  • vascular function as pressure-strain elasticity modu-
lus (kPa), blood pressure,
  • metabolic control with HbA1c, fasting plasma glu-
cose, lipid profile, serum insulin, proinsulin, body 
weight and
  • cardiovascular risk/adverse events as mentioned 
above.
Echocardiography
Patients were examined while in the left lateral decu-
bitus position using a commercially-available system 
(SSD-5500, ALOKA, Tokyo, Japan) equipped with tissue 
Doppler imaging and a 2.5–5  MHz phased array trans-
ducer. The ECG was simultaneously recorded. Stand-
ardized cross-sectional 2-dimensional and M-mode 
echocardiography [16] was used to measure the short 
axis left ventricular dimensions in the parasternal long 
axis view and the longitudinal left atrial diameter in the 
apical view. Pulsed wave Doppler imaging of the transmi-
tral inflow was used to assess the traditional parameters 
of left ventricular diastolic function: early (E) and late 
diastolic (A) velocities and E/A.
163 paents assessed for eligibility
39  excluded
33  did not meet inclusion
or met exclusion criteria
6  declined to parcipate
124 randomized
1 non-compliance
12 withdrew consent,  
1 physical inability
1 non-compliance
13 lost to follow-up




4 loss of contact




4  private reasons
2 loss of contact
61 analyzed
by tradional stascs and 
by mulple imputaon technique
48 analyzed
by tradional stascs and 
by mulple imputaon technique
62 allocated to HI62 allocated to AI Allocaon
48 received HI61 received AI
Analysis
Follow up
Fig. 1 Trial profile for the long‑term RCT study MDI with analogue (AI) versus human insulin (HI) in type 2 diabetes
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Global left ventricular function by pulsed tissue Doppler
As described above, tissue Doppler imaging was per-
formed by one experienced cardiologist [5, 17, 18]. In 
short, peak systolic velocity (S’), early diastolic velocity 
(E’) and late diastolic velocity (A’) were averaged from 
six basal myocardial regions (apical 4-, 3- and 2-cham-
ber view) as a measure of global left ventricular func-
tion. Given the steep and known decline of early diastolic 
myocardial velocity by 1 % every year due to physiologic 
aging in normal non-diabetic persons, individual patients 
were classified as subject to dysfunction if the measured 
diastolic velocity E’ was lower than the age-related cut 
off level deemed normal as calculated by the respective 
regression equation [18]. Left ventricular filling pressure 
was calculated as E/E’.
Vascular ultrasound
Using standardized methods at the right common 
carotid artery, intima media thickness was measured 
using a 13 MHz linear array transducer. The arterial stiff-
ness parameters elasticity modulus ε and pulse wave 
velocity (PWV) were measured using a combined Dop-
pler and echo-tracking system (SSD-5500, ALOKA, 
Tokyo, Japan) that provided online calculation taken 
from instantaneous intravascular diameter and pressure 
changes as previously described [5, 19]. During vascular 
imaging, blood pressure was measured three times at the 
left arm by an automated cuff sphygmomanometer and 
averaged.
Laboratory
Fasting plasma glucose, serum insulin and lipid profile, 
glycated hemoglobin A1c (HbA1c) and high-sensitive 
C-reactive protein (hsCRP) were determined according 
to routine methods at the Department of Clinical Chem-
istry (Klinikum rechts der Isar, Technical University, 
Munich). Intact proinsulin was assessed in representative 
subgroups (AI n = 36 and HI n = 31) by the IKFE insti-
tute, Mainz [20].
Statistics
Drawing from experience in an earlier study comparing 
analogue with human insulin therapy over the course of 
1 year, a difference of 10 ± 19 mg/dl in postprandial glu-
cose between the treatment groups [12] was expected. In 
order to detect this difference with a power of 80 % at a 
5 % significance level, each treatment group would need 
to have 58 patients. For the secondary endpoint diastolic 
myocardial velocity, a difference of 0.6 ± 1.1 cm/sec was 
expected between the groups. The two-tailed T test with 
n = 58/group would then yield a power of 82 %. Assum-
ing an expected drop out rate of 10  %, the unpredict-
ability of standard deviations and the test result for the 
secondary endpoint diastolic myocardial velocity,  ≥60 
patients would be necessary for each treatment arm.
Statistical analyses were performed using the SPSS 
version 18.0 software package for windows (SPSS Inc, 
Chicago, IL). Data was expressed as mean  ±  standard 
deviation when normally distributed and otherwise as 
median {interquartile range}. The difference between 
baseline and endpoint measurements of a specific 
parameter was calculated as delta (Δ) and the difference 
between postprandial and fasting values as a postpran-
dial excursion. Students’ T test or nonparametric tests 
were used for group comparisons where appropriate. 
The study data were analyzed in conventional statistics. 
To compensate for the uncertainty caused by missing 
values from drop-out individuals, data were additionally 
analyzed using the multiple imputation technique with 
10 replacements at random in order [21] based on the 
confirmation that the missing pattern was completely at 
random [22]; these results are presented in brackets [ ]. 
Bivariate correlations were assessed using Pearson’s cor-
relation coefficients.
Role of the funding source
The study design, protocol and statistical plan of this 
investigator-initiated study were provided by both first 
and the last authors and were agreed upon by the study 
sponsor who supplied the study products. The authors 
alone contributed to data collection, interpretation and 
writing of the report and take full responsibility for its 
content.
Results
There were no significant differences between the pre-
study insulin regimens of the different treatment groups 
with regards to analogue or human insulin, basal bolus or 
other insulin strategies. Participants of both study groups 
were comparable for demographic, hemodynamic, car-
diac and metabolic data including cardiovascular risk 
factors and concomitant medication (Table 1).
Of the 109 patients, 5 patients in group AI and 4 in 
group HI were lost to follow-up at the 24-month visit, 
and 8 patients in each group at the 36-month visit (Fig. 1). 
The resulting data were analyzed both using conven-
tional statistics and the multiple imputation technique 
as shown in brackets [ ]. The mean treatment period was 
32 ± 7 months.
At 36 months, the daily insulin dose per kg body weight 
had significantly increased: by 0.07 ± 0.28 U/kg with AI 
and by 0.18  ±  0.26  IU/kg with HI (inter-group signifi-
cance p  =  0.054). Weight had increased from baseline 
to month 36 with AI by 2.3 ± 7.8 kg (p = 0.050) and by 
2.8 ± 7.6 kg (p = 0.038) with HI (inter-group significance 
p = 0.774).
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At 36  months (Table  2), the primary endpoint, post-
prandial glucose, had decreased by 20  ±  62  mg/dl 
(p  =  0.038) with AI but had a non-significant increase 
by 9 ± 53 mg/dl (p = 0.33) with HI thereby resulting in 
a significant difference between the groups (p  =  0.032 
[p = 0.047]). Simultaneously, the postmeal glucose levels 
(161 ± 39 with AI vs. 195 ± 54 mg/dl with HI) were rel-
evantly and significantly different (p = 0.002 [p = 0.010]) 
as were the postmeal glucose excursions (15 ± 43 with AI 
vs. 57 ± 40 mg/dl with HI, p = 0.001 [p = 0.007]).
Table 1 Demographics and baseline data of patients
Mean ± SD or median {interquartile range} respectively
pp postmeal, S’ systolic myocardial velocity, E’ early diastolic myocardial velocity, LV left ventricular, E/E’ estimated LV filling pressure
a Data from representative subgroups (AI = 36 and HI = 31)
Analogue insulin  
group AI (n = 61)
Human insulin  
group HI (n = 48)
p
Age Years 60.4 ± 9.5 63.1 ± 10.6 0.159
Sex male n (%) 46 (75) 31 (65) 0.218
BMI kg/m2 32 ± 5 32 ± 6 0.709
Duration of diabetes Years 10 {5–15} 9.5 {5–14} 0.580
Insulin dose MDI IE/d 56 {37–83} 50 {36–70} 0.485
Metformin n (%) 13 (21) 16 (33) 0.159
Hypertension n (%) 58 (95) 42 (88) 0.153
Smoking n (%) 17 (28) 15 (31) 0.700
Myocardial infarction n (%) 14 (23) 8 (17) 0.417
Betablocker n (%) 23 (38) 18 (38) 0.983
ACE‑inhibitor n (%) 37 (60) 33 (69) 0.224
Calcium channel blocker n (%) 9 (15) 10 (21) 0.406
AT1 blocker n (%) 15 (25) 8 (17) 0.314
Diuretics n (%) 23 (38) 20 (42) 0.674
Statins n (%) 28 (46) 25 (52) 0.522
Aspirin n (%) 30 (49) 23 (48) 0.896
Glucose fasting mg/dl 163 ± 54 163 ± 45 0.962
Glucose pp mg/dl 183 ± 69 185 ± 50 0.870
HbA1c % 7.3 ± 1.7 7.7 ± 1.8 0.237
Intact proinsulina pmol/l 5 {2.7–7.6} 4.8 {3.2–8.2} 0.515
Triglycerides mg/dl 137{102–177} 117 {94–184} 0.463
Cholesterol mg/dl 187 ± 36 188 ± 42 0.890
LDL mg/dl 114 ± 34 113 ± 37 0.941
HDL mg/dl 46 {38–53} 48 {39–54} 0.543
Creatinine mg/dl 0.9 {0.8–1.08} 0.9 {0.7–1.1} 0.493
ASAT U/l 29 {24–40} 27 {23–39} 0.862
CRP mg/dl 0.28 {0.13–0.5} 0.3 {0.15–0.58} 0.552
S’ cm/s 7.6 ± 1.1 7.6 ± 1 0.984
E’ cm/s 7.8 ± 1.4 8.2 ± 1.7 0.168
LV end‑diastolic diameter mm 44 {42–48} 44 {41–48} 0.776 
Septal thickness mm 12 {11–14} 12 {11–13} 0.449
Mitral E/A 0.9 {0.7–1.1} 0.9 {0.8–1.1} 0.651
E/E’ mmHg 8.9 {7.5–10.9} 8.1 {7.0–9.6} 0.174
Intima media thickness mm 0.7 ± 0.2 0.7 ± 0.2 0.714Εlasticity modulus Ɛ kPa 140 {113–228} 165{136–259} 0.087
Pulse wave velocity m/s 7.3 {6.6–9.2} 8.3 {7.0–9.9} 0.151
Heart rate bpm 71 {63–78} 69 {64–80} 0.509
Systolic blood pressure mmHg 140 {129–152} 140{123–150} 0.712
Diastolic blood pressure mmHg 83 ± 12 81 ± 9 0.321
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Within the metabolic secondary endpoints, fasting 
glucose did not significantly decrease with AI but did 
significantly decrease with HI (Table  2) to comparable 
levels in both groups (150 ± 34 with AI vs. 144 ± 40 mg/
dl with HI, p  =  0.433). Intact proinsulin in the fasting 
state decreased insignificantly with AI and increased 
insignificantly with HI, resulting in a significant dif-
ference between these changes (p  =  0.048). HbA1c 
decreased by 0.4 ± 1.5 %, p = 0.063 [p = 0.011] with AI 
and by 1.3 ± 1.8 %, p = 0.001 [p = 0.001] with HI. This 
larger decrease (p = 0.024 [p = 0.082]) resulted in com-
parable levels (6.7 ± 0.8 % with AI vs. 6.5 ± 0.7 % with 
HI, p =  0.486). Only with HI did fasting and postpran-
dial serum triglyceride levels increase significantly as 
did serum creatinine with a trend to significance for this 
change between the groups (Table 2).
Within the cardiovascular secondary endpoints, there 
was no significant change of E’ with HI (Table 2) but post-
meal E’ improved with AI by 0.6 ± 1.4 cm/s, p = 0.009 
[p = 0.002] and fasting E’ as a trend in traditional statis-
tics (by 0.4 ±  1.4  cm/s, p =  0.069) and significantly by 
multiple imputation analysis [0.5 ± 1.4 cm/s, p = 0.013]. 
Accordingly, diastolic dysfunction [12] was reduced by 
22 % with AI and by 12 % with HI. The traditional param-
eter of diastolic function, E/A, significantly improved 
with AI, both in the fasting state and postmeal, and as 
a trend with HI (Table 3). The mitral inflow E increased 
significantly postmeal with AI but decreased as a trend 
with HI. With values close to normal, E/E’ did not change 
significantly. None of the changes in diastolic function 
parameters achieved significance between the treatment 
groups.
Table 2 Changes at 36 months from baseline
Italics p values indicate significant changes at 36 months
Mean ± SD or median {interquartile range} respectively; additional results from multiple imputation analysis in brackets [ ]
pp postprandial, LV left ventricular, E/E’ estimated LV filling pressure, EA ratio of mitral inflow velocities, IMT intima media thickness, PWV pulse wave velocity, BP blood 
pressure
a Data from representative subgroups (A = 36 and H = 31)










Glucose fasting (mg/dl) −7 [−12] ± 52 [53] 0.375 [0.095] −17 [−19] ± 42 [44] 0.021 [0.008] 0.336 [0.510]
Glucose pp (mg/dl) −20 [−20] ± 62 [64] 0.038 [0.021] 9 [4] ± 53 [56] 0.335 [0.676] 0.032 [0.047]
HbA1c (%) −0.4 [−0.6] ± 1.5 [1.7] 0.063 [0.011] −1.3 [−1.2] ± 1.8 [1.7] 0.000 [0.000] 0.024 [0.082]
Intact proinsulina (pmol/l) −0.9 {−2.3 to 0.8} 0.171 0.3 {−0.9 to 2.7} 0.199 0.048
Triglycerides (mg/dl) 0 [1] {−12 [−18] to 33 [34]} 0.496 [0.577] 11 [8] {6 [−15] to 41 [41]} 0.016 [0.167] 0.153 [0.467]
Triglycerides pp (mg/dl) 10 [9] {−15 [−22] to 39 [45]} 0.081 [0.198] 24 [17] {−4 [−10] to 64 [55]} 0.023 [0.040] 0.317 [0.424]
Cholesterol (mg/dl) 10 [10] ± 49 [50] 0.161 [0.186] 6 [6] ± 43 [42] 0.437 [0.375] 0.668 [0.699]
LDL (mg/dl) 5 [3] ± 40 [43] 0.420 [0.685] −7 [−5] ± 39 [38] 0.262 [0.408] 0.170 [0.367]
HDL (mg/dl) 1 [0] {−3 [−5] to 4 [5]} 0.636 [0.628] 2 [1] {−6 [−6] to 9 [9]} 0.493 [0.487] 0.844 [0.668]
Creatinine (mg/dl) 0 [0] {−0.10 [−0.10] to 0.10 [0.10]} 0.954 [0.710] 0.10 [0.09] {0 [−0.03] to 0.10 [0.15]} 0.018 [0.009] 0.054 [0.064]
ASAT U/l −2 [−1] {−7 [−11] to 3 [6]} 0.096 [0.400] 1 [1] {−4 [−11] to 10 [11]} 0.586 [0.734] 0.126 [0.554]
hsCRP (mg/dl) 0 [−0.01] {−0.18 [−0.24] to 0.1 
[0.14]}
0.468 [0.521] 0.05 [0.01] {−0.1 [−0.19] to 0.15 
[0.18]}
0.307 [0.669] 0.199 [0.525]
LV enddiast. diameter (mm) 2 [2] {−2 [−2] to 6 [5]} 0.041 [0.032] 1 [1] {0 [−1] to 3 [3]} 0.149 [0.151] 0.387 [0.395]
Septal thickness (mm) 0 [−0.1] {−2 [−1.4] to 2 [2]} 0.948 [0.733] 0 [0] {−2 [−1.6] to 1 [1.7]} 0.718 [0.706] 0.768 [0.722]
Post. wall thickness (mm) 1 [0.8] {−1 [−0.9] to 2 [1.4]} 0.103 [0.082] 1 [0.9] {0 [−0.4] to 2 [2]} 0.010 [0.012] 0.388 [0.501]
S’ (cm/s) 0 [0] ± 0.8 [0.8] 0.889 [0.801] 0.1 [0.1] ± 1 [0.9] 0.504 [0.571] 0.516 [0.753]
E’ (cm/s) 0.4 [0.5] ± 1.4 [1.4] 0.069 [0.013] 0.1 [0] ± 1.3 [1.3] 0.738 [0.853] 0.312 [0.059]
E’ pp (cm/s) 0.6 [0.6] ± 1.4 [1.4] 0.009 [0.002] 0.2 [0.1] ± 1.4 [1.5] 0.435 [0.430] 0.241 [0.110]
E/E’ (mmHg) −0.1 [−0.01] {−1.52 [−1.54] to 
1.54 [1.46]}
0.870 [0.657] 0.35 [0.25] {−0.9 [−1.02] to 1.99 
[1.98]} 
0.136 [0.182] 0.192 [0.198]
IMT (mm) 0.03 [0.05] ± 0.17 [0.18] 0.200 [0.048] 0.06 [0.07] ± 0.19 [0.18] 0.091 [0.018] 0.551 [0.649]
Elasticity modulus (kPa) 15 [8] {−36 [−40] to 49 [60]} 0.363 [0.463] 30 [8] {−41 [−65] to 78 [68]} 0.313 [0.622] 0.643 [0.740]
PWV (m/s) 0.2 [0.1] {−0.9 [−0.9] to 0.9 [1.1]} 0.684 [0.494] 0.5 [0] {−1 [−1.4] to 1.7 [1.4]} 0.319 [0.622] 0.448 [0.693]
Heart rate (bpm) −4 [−4] {−10 [−10] to 5 [4]} 0.057 [0.026] −4 [−4] {−7 [−7] to 3 [3]} 0.026 [0.079] 0.920 [0.630]
Systolic BP (mmHg) 3 [7] {−9 [−9] to 20 [20]} 0.175 [0.087] 20 [17] {−5 [−4] to 29 [29]} 0.008 [0.002] 0.065 [0.075]
Diastolic BP (mmHg) 5 [5] ± 12 [12] 0.005 [0.003] 10 [11] ± 12 [12] 0.000 [0.000] 0.062 [0.064]
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Compared to HI, treatment with AI tended to result 
in smaller increases in systolic and in diastolic blood 
pressure (Table  2). In parallel, vascular stiffness was 
lower after 36 months of therapy, expressed as elasticity 
modulus ε (154 {105–204} vs. 182 {148–234} kPa in HI, 
p = 0.028 [p = 0.198].
After 36 months, there were two cardiovascular events 
with AI (myocardial infarctions) vs. five events with HI 
(one myocardial infarction, four strokes), equivalent to 
event-free percentages of 96 vs. 81 % (p = 0.142). Anti-
hypertensive medication remained comparable between 
both groups.
Discussion
This prospective, randomized, open, controlled trial 
showed that long-term MDI with AI in patients with type 
2 diabetes resulted in better postprandial glucose control 
than MDI with HI. This benefit with AI was associated 
with improved diastolic cardiac function whereas this 
function remained unchanged with HI.
The improvement of the primary endpoint postmeal 
glucose levels following an MDI with AI regimen could 
be mainly attributed to the effects of the short-acting ana-
logues. This effect has been shown in type 1 and in type 
2 diabetes [12, 14, 23, 24]. The study design also provided 
a potentially beneficial effect from the basal analogue 
insulin which should result in a relative protection of 
the beta-cell from the flatter and longer action profile of 
the basal insulin [14]. An augmented beta-cell function 
may also be related to an improvement in insulin resist-
ance. Our data suggest an at least relative improvement 
of insulin resistance by the unchanged triglycerides lev-
els with AI versus the significant rise with HI—in spite of 
similar weight changes and identical nutritional recom-
mendations in both groups.
By contrast to these specifically different metabolic 
effects, both treatment regimens improved long-term 
glucose control to a similar HbA1c level after 36 months. 
This similarity in long-term glucose control may result 
from three aspects: first, a compensation of the lower 
postprandial glucose levels by the higher fasting glu-
cose levels in the analogue regimen and vice versa of 
the higher postprandial glucose levels by the lower fast-
ing levels with HI. Second, a numerically higher base-
line HbA1c level in the HI group (7.7 vs. 7.3 %, Table 1) 
allowed for a more pronounced lowering; and third, a 
more pronounced increase in the daily insulin dose per 
kg body weight with HI.
Comparative trials using the same target for MDI with 
different insulin types allow for minimizing potential 
differences in glucose control so that differences in car-
diovascular risk may be assessed. In the presence of com-
parable fasting glucose and HbA1c levels, the results can 
thereby be interpreted for ultimate risk–benefit assess-
ments including diastolic cardiac function. Improvement 
of diastolic dysfunction, that is the antecedent to dias-
tolic heart failure i.e. heart failure with preserved ejec-
tion fraction (HFpEF), has been a challenging topic in 
the treatment of patients with type 2 diabetes. Remark-
ably, there is no evidence-based therapy available against 
HFpEF [2]. Diastolic dysfunction has high prevalence in 
overweight individuals with type 2 diabetes [2, 6, 18] and 
results in a poor prognosis and reduced quality of life 
because of the associated limitation of physical activi-
ties in daily life. However, it is under-diagnosed in clini-
cal routine and lacks evidence-based treatment strategies 
due to problems associated with the bashful and resigned 
obese patients [6], with the measuring technique [6, 18] 
and with the understanding of the complex underlying 
mechanisms [25–27].
With regards to diagnostic issues stemming from the 
measuring technique, quantitative pulsed tissue Dop-
pler imaging emerged 20  years ago and has since pro-
vided very good results for the sensitive measurement 
of myocardial velocity E’ during early diastole [26], with 
good feasibility even in overweight individuals at bed-
side, sensitivity to energy restraint, correlation to exercise 
capacity, prognostic value and the potential to monitor 
Table 3 Parameters of  diastolic function in  the fasting 
state and post meal (pp)
Italics p values indicate significant changes at 36 months
Mean ± SD or median {interquartile range} respectively
E’ early diastolic myocardial velocity by tissue Doppler, E early diastolic mitral 
inflow velocity, A late diastolic mitral inflow velocity, E/A ratio of mitral inflow 
velocities, E/E’ estimated LV filling pressure
Parameter MDI insulin 
regimen
At baseline At 36 months p
E’ (cm/s) Analogue 
Human
7.8 ± 1.4 
8.2 ± 1.7




E’ pp (cm/s) Analogue 
Human
7.6 ± 1.6 
8.1 ± 1.8






0.96 ± 0.3 
0.93 ± 0.25




E/A pp Analogue 
Human
0.94 ± 0.30 
0.92 ± 0.26




E (cm/s) Analogue 
Human
70 ± 17 
70 ± 20




E pp (cm/s) Analogue 
Human
71 ± 18 
74 ± 20




A (cm/s) Analogue 
Human
76 ± 18 
75 ± 21




A pp (cm/s) Analogue 
Human
71 ± 18 
74 ± 20
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therapeutic interventions [6, 28]. Furthermore, E’ allows 
for the quantification of diastolic dysfunction by using 
the dominant influence of aging on E’ [18], which is 
essential for the mathematically-correct identification of 
risk factors and for the diagnosis of dysfunction/HFpEF. 
In line with earlier reports [2, 6] diastolic dysfunction 
was highly prevalent in the study cohort and was normal-
ized in 22 % of the patients on AI treatment vs. 12 % of 
the patients on HI treatment.
In the present study design, E’ was averaged from 6 
basal myocardial regions and, therefore, taken as meas-
ure of global left ventricular function. The increase of E’ 
with AI was mirrored by the decrease of the traditional 
parameter E/A in the fasting state and postmeal. Accord-
ingly, this study demonstrated a long-term improvement 
in diastolic function using MDI with AI (Table 3). How-
ever, the third parameter of diastolic function, the ratio 
E/E’, did not change significantly with the treatment 
interventions due to the parallel modifications of E and E’ 
(Table 3). This thereby substantiated concerns in earlier 
reports that this estimation of LV filling pressure may be 
a less sensitive measure of diastolic function, especially in 
metabolic disease with its predominantly mild degree of 
diastolic dysfunction [18, 29].
It is of interest that the observed changes in diastolic 
function were more distinct in the postmeal state. As for 
the complex mechanisms and potential factors that may 
influence diastolic dysfunction [18,  25], this study did 
not demonstrate any improvement in the hemodynamic 
factors blood pressure or vascular stiffness. Within meta-
bolic factors, fasting glucose and HbA1c had improved 
to comparable levels at 36  months. In line with recent 
reports [30–32], these data do not support an automatic 
translation of improved glycemic control into augmented 
cardiac function. Improvements in postprandial glucose 
excursions with AI were paralleled by functional amelio-
ration, whereas the HI group demonstrated excessively 
high levels of postmeal glucose and its variability. These 
observations rather support the importance of control-
ling postprandial glucose and the underlying insulin 
resistance as therapeutic targets for improvement of car-
diac function [3], at least in moderately well-controlled 
type 2 diabetes, in line with earlier reports [5, 18, 27, 28, 
31, 33].
Pharmacological therapy with MDI or rosiglitazone and 
maintaining an adequate diet [5, 28, 34] have been seen to 
improve diastolic cardiac function in type 2 diabetes along 
with improved postmeal glucose. This is in agreement 
with the reported link between acute glucose fluctua-
tions and activation of oxidative stress [35]. A recent study 
demonstrated an immediate and highly repetitive deterio-
ration of cardiac function after a carbohydrate meal asso-
ciated with increased oxidative stress in overweight and 
insulin-dependent patients with type 2 diabetes [36]. The 
reverse being also true, cardiac function has been shown 
to improve when adhering to diets that effectively lower 
weight or at least postprandial glucose levels [28, 34, 37, 
38]. Small pharmacological studies have suggested posi-
tive effects on diastolic dysfunction from optimized meta-
bolic control in patients with type 1 and type 2 diabetes 
[6] in particular by improving postmeal glucose control, 
insulin resistance and reducing oxidative stress [5, 37]. By 
using a practical combination of therapeutic strategies in 
the form of adapted anti-diabetic medication and adher-
ing to effective nutrition [28, 39] in line with the most 
recent dietary treatment guidelines [40], improved post-
meal glucose control appears to be a promising target for 
the improvement of diastolic dysfunction.
The underlying biochemical mechanisms are complex 
and not yet fully understood. Important metabolic mech-
anisms imply that a reduction of insulin resistance [28, 
31, 37], oxidative stress and augmented NO bioavailabil-
ity [28, 41, 42] enhance both cardiac efficiency i.e. intra-
cardiocyte energy production [43, 44] and endothelial 
function that translates into augmented myocardial per-
fusion and function. Indeed, small clinical studies in type 
2 diabetes have demonstrated that improved metabolic 
control may enhance myocardial perfusion and function 
[4] and that short-acting analogue insulin normalizes 
myocardial perfusion in the postmeal state by 35 % when 
compared to being left untreated [45]. When looked at 
together, these observations and the present study sug-
gest that analogue insulin may result in optimized post-
meal regulation of myocardial perfusion and hence 
diastolic function in type 2 diabetes. Because of its sig-
nificant clinical relevance, further studies which explore 
the major mechanisms of postmeal (dys-) regulation of 
myocardial perfusion in diabetic individuals would be 
highly welcome.
It is conceivable that other more underlying mecha-
nisms for diastolic dysfunction relate to insulin resistance 
[27, 33], as also suggested from more recent studies [3, 
18, 32, 43]. For the present insulin-dependent patients 
with diabetes, however, the assessment of insulin resist-
ance cannot be based on the HOMA-IR, but rather on 
surrogate parameters such as the daily insulin dose. The 
insulin dose per kg body weight increased by 0.07 U/kg 
with AI vs. 0.19  IU/kg (p =  0.054) with HI. Other sur-
rogate parameters are the triglyceride levels which 
remained unchanged with AI but increased with HI 
therapy both fasting and postmeal. These data indicate 
not only the degree of impact insulin resistance has as 
a therapeutic target in type 2 diabetes. It also suggests 
selecting analogue over human MDI, possibly due to the 
amelioration of postmeal blood glucose excursions with 
the consequent reduction of acute glucose toxicity. In 
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this respect, an insulin pump therapy using short-acting 
insulin analogues may be an even more interesting model 
for patients with type 2 diabetes: Glucose variability is 
further reduced compared to a MDI with short and long-
acting insulin analogues [46].
Much more knowledge is needed with regards to the 
effects and reversibility of insulin resistance for optimiz-
ing fat and glucose dysmetabolism—especially postmeal 
[47]. Clinical studies are needed which take into account 
well-defined metabolic and lifestyle characteristics so 
that treatment strategies can evolve that make use of the 
inherent reversibility potential from postprandial glucose 
and fat dysmetabolism. This affects both the evaluation of 
traditional anti-diabetic medication and the most recent 
therapeutic developments [48, 49].
In spite of the improvements in postprandial metabolic 
control and diastolic cardiac function by AI, cardiovascu-
lar events were not significantly different between both 
treatment groups. This is due to the low patient number 
(n = 109) event rate (group A: 2 events; group H: 5 events) 
and observation period in comparison to the Steno study 
(n  =  180; observation period 13.3  years) or the UKPD 
study (n = 5102; 20 years [10, 50]. Given the prognostic 
value of diastolic cardiac function, this study promotes 
the use of more actual measures of positive clinical out-
come, such as diastolic cardiac function, to assess thera-
peutic efficiency in the treatment of type 2 diabetes.
Limitations
Several study limitations need to be addressed. One of 
these is the considerable number of patients who with-
drew their study participation consent or were lost during 
follow up. However, the results nevertheless demonstrated 
a significant outcome for the primary endpoint indicating 
that the study had indeed remained sufficiently powered. 
In order to evaluate the problem of missing data, an addi-
tional statistical technique, the multiple imputation tech-
nique [21, 22], was applied that was specifically developed 
for analyzing data sets with missing entries. The similarity 
of these results to the results from traditional statistical 
analysis supports the relevance of the study data and their 
statistical meaning in spite of the drop-out rate.
The larger number of patients in the human insulin 
group withdrawing their participation consent before 
the onset of therapy may have introduced a retrospec-
tive randomization bias. However, patients were free to 
withdraw participation at any time during the study and 
it seems a number had signed consent only in the hope 
to be randomized to a more modern and more expen-
sive analogue insulin. These patients, in particular, were 
very motivated to apply optimal anti-diabetic care so 
that their absence may have contributed to the initially 
slightly higher HbA1c level in the human insulin group.
The study design did not allow for diagnosing and 
assessing insulin resistance by HOMA-IR in the insulin-
dependent patients with type 2 diabetes. An assessment by 
clamp technique would have been beyond the scope of this 
study. Altogether, this diagnostic problem simply reflects 
an unsolved but important issue for the tailoring of opti-
mal metabolic control in diabetology and should be fur-
ther evaluated with respect to the specific effects of dietary 
and/or exercise intervention in support of pharmaceutical 
treatment in different stages of insulin resistance.
The improvement of diastolic cardiac function with 
AI compared to the unchanged function with HI did 
not result in inter-group significance in the fasting state 
(p = 0.312 [p = 0.059] or postmeal (p = 0.241 [p = 0.110] 
due to an unexpectedly high standard deviation of the 
change from baseline, so that the study turned out under-
powered for comparative assessment of cardiac func-
tion. This limitation, however, should not detract from 
the clinically-relevant message that MDI with AI does 
improve diastolic cardiac function in moderately well-
controlled patients with type 2 diabetes.
Conclusions
This report provides evidence from a randomized con-
trolled long-term study that multiple daily injection 
therapy with analogue insulin is superior for the control 
of postprandial glucose in comparison to human insulin. 
Additionally, MDI with AI is associated with improved 
diastolic cardiac function. This is a step forward in the 
treatment of diabetic patients with diastolic dysfunction 
who are at risk for heart failure with preserved ejection 
fraction. Further exploration is warranted as to the impact 
of postmeal glucose excursions and the underlying insulin 
resistance for the regulation of myocardial perfusion both 
with the help of lifestyle changes and anti-diabetic medi-
cation. For the benefit of the patients, it would be helpful 
for future studies to also include measures of actual clini-
cal outcome, such as diastolic cardiac function, in addi-
tion to traditional cardiovascular endpoints.
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